Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

Arboviral Encephalitis

Arboviral Encephalitis

Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Viral Meningitis

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial.

BMJ neurology open·2025

Same author

Choroid plexus enlargement in secondary progressive MS: phenotype comparison.

Multiple sclerosis and related disorders·2025

Same author

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.

Brain : a journal of neurology·2025

Same author

COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of Protection.

Neurology(R) neuroimmunology & neuroinflammation·2025

Same author

Choroid Plexus Enlargement in Secondary Progressive MS: phenotype comparison.

medRxiv : the preprint server for health sciences·2025

Same author

Utility of icobrain for brain volumetry in multiple sclerosis clinical practice.

Multiple sclerosis and related disorders·2024

Search research articles

Related Experiment Video

Updated: May 23, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Neuromyelitis optica: not a multiple sclerosis variant.

Michael H Barnett¹, Ian Sutton

¹Department of Neurology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia. michael.barnett@sydney.edu.au

Current Opinion in Neurology

|April 11, 2012

Summary

This summary is machine-generated.

Neuromyelitis optica (NMO) is a distinct disease, not a multiple sclerosis variant, identified by NMO-immunoglobulin G (NMO-IgG) targeting aquaporin 4 (AQP4). Understanding NMO pathogenesis guides targeted therapies.

More Related Videos

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Related Experiment Videos

Last Updated: May 23, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Area of Science:

Neuroimmunology
Neuropathology
Clinical Neurology

Background:

Neuromyelitis optica (NMO) was historically misclassified as a variant of multiple sclerosis (MS).
The discovery of NMO-specific autoantibodies, NMO-immunoglobulin (Ig)G, targeting aquaporin 4 (AQP4) has established NMO as a distinct disease entity.
Divergent immunopathogenesis and treatment responses necessitate accurate differentiation between NMO and MS at disease onset.

Purpose of the Study:

To review recent pathological, imaging, and clinical trial data in NMO.
To discuss emerging concepts in NMO molecular immunopathogenesis.
To inform the development of targeted therapies for NMO.

Main Methods:

Review of recent neuropathological studies on NMO lesions.
Analysis of imaging findings in NMO patients, including atypical presentations.
Characterization of NMO-IgG binding to AQP4 isoforms and investigation of novel disease models.

Main Results:

Neuropathology reveals perivascular astrocyte destruction and relative myelin preservation in early NMO, distinguishing it from MS.
Diagnostic biomarkers are crucial for identifying NMO in patients with limited or atypical symptoms.
Studies have elucidated complement-mediated and cell-mediated mechanisms of astrocyte injury in NMO.

Conclusions:

NMO-IgG positive NMO is definitively not a variant of MS.
Further research is needed to understand the pathogenesis of NMO in aquaporin 4 antibody-negative cases.
Current NMO therapies are limited by trial design; targeted treatments based on enhanced immunopathogenesis understanding are forthcoming.